The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
B-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affecting certain genes, contribute to relapses and re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2023-09-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/8791 |
| _version_ | 1827317544300576768 |
|---|---|
| author | Hastono Ridwansyah Indra Wijaya Muhammad Hasan Bashari Achmad Hussein Sundawa Kartamihardja Bethy Suryawathy Hernowo |
| author_facet | Hastono Ridwansyah Indra Wijaya Muhammad Hasan Bashari Achmad Hussein Sundawa Kartamihardja Bethy Suryawathy Hernowo |
| author_sort | Hastono Ridwansyah |
| collection | DOAJ |
| description | B-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affecting certain genes, contribute to relapses and refractory cases. Chidamide (tucidinostat) is a novel histone deacetylase inhibitor that can reverse this epigenetic imbalance and has been approved for the treatment of T-cell malignancies. However, the use of chidamide for B-NHL remains limited, and the lack of relevant literature exacerbates this limitation. We conducted this review to summarize the anticancer activity of chidamide against B-NHL and its clinical applications to overcome drug resistance. This systematic review was conducted according to the PRISMA 2020 guidelines, using some keyword combinations from MEDLINE and EBSCO. The inclusion and exclusion criteria were also defined. Of the 131 records retrieved from databases, 16 were included in the review. Nine articles revealed that chidamide limited tumor progression by modifying the tumor microenvironment, stopping the cell cycle, inducing apoptosis and autophagy, and enhancing complement-dependent and antibody-dependent cell-mediated cytotoxicities.According to seven other studies, administering chidamide in combination with another existing therapeutic regimen may benefit not only patients with relapsed/refractory B-NHL, but also those with newly diagnosed B-NHL. Chidamide plays many important roles in limiting B-NHL progression through epigenetic modifications. Thus, combining chidamide with other anticancer drugs may be more beneficial for patients with newly diagnosed and relapsed/refractory B-NHL.
|
| first_indexed | 2024-04-24T23:40:38Z |
| format | Article |
| id | doaj.art-dfe1cb5784014dff8c4998ed01a9e092 |
| institution | Directory Open Access Journal |
| issn | 2831-0896 2831-090X |
| language | English |
| last_indexed | 2024-04-24T23:40:38Z |
| publishDate | 2023-09-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj.art-dfe1cb5784014dff8c4998ed01a9e0922024-03-15T13:22:31ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2023-09-0123510.17305/bb.2023.8791The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic reviewHastono Ridwansyah0https://orcid.org/0000-0003-2737-6203Indra Wijaya1Muhammad Hasan Bashari2Achmad Hussein Sundawa Kartamihardja3Bethy Suryawathy Hernowo4Doctoral Study Program, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; Department of Biomedicine, Faculty of Medicine, President University, Bekasi, IndonesiaDivision of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, IndonesiaDepartment of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, IndonesiaDepartment of Nuclear Medicine and Molecular Theranostic, Faculty of Medicine, Universitas Padjadjaran, Bandung, IndonesiaDepartment of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran, Bandung, IndonesiaB-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affecting certain genes, contribute to relapses and refractory cases. Chidamide (tucidinostat) is a novel histone deacetylase inhibitor that can reverse this epigenetic imbalance and has been approved for the treatment of T-cell malignancies. However, the use of chidamide for B-NHL remains limited, and the lack of relevant literature exacerbates this limitation. We conducted this review to summarize the anticancer activity of chidamide against B-NHL and its clinical applications to overcome drug resistance. This systematic review was conducted according to the PRISMA 2020 guidelines, using some keyword combinations from MEDLINE and EBSCO. The inclusion and exclusion criteria were also defined. Of the 131 records retrieved from databases, 16 were included in the review. Nine articles revealed that chidamide limited tumor progression by modifying the tumor microenvironment, stopping the cell cycle, inducing apoptosis and autophagy, and enhancing complement-dependent and antibody-dependent cell-mediated cytotoxicities.According to seven other studies, administering chidamide in combination with another existing therapeutic regimen may benefit not only patients with relapsed/refractory B-NHL, but also those with newly diagnosed B-NHL. Chidamide plays many important roles in limiting B-NHL progression through epigenetic modifications. Thus, combining chidamide with other anticancer drugs may be more beneficial for patients with newly diagnosed and relapsed/refractory B-NHL. https://www.bjbms.org/ojs/index.php/bjbms/article/view/8791Chidamidetucidinostathistone deacetylase (HDAC)histone deacetylase inhibitorsnon-Hodgkin lymphoma (NHL) |
| spellingShingle | Hastono Ridwansyah Indra Wijaya Muhammad Hasan Bashari Achmad Hussein Sundawa Kartamihardja Bethy Suryawathy Hernowo The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review Biomolecules & Biomedicine Chidamide tucidinostat histone deacetylase (HDAC) histone deacetylase inhibitors non-Hodgkin lymphoma (NHL) |
| title | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
| title_full | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
| title_fullStr | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
| title_full_unstemmed | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
| title_short | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
| title_sort | role of chidamide in the treatment of b cell non hodgkin lymphoma an updated systematic review |
| topic | Chidamide tucidinostat histone deacetylase (HDAC) histone deacetylase inhibitors non-Hodgkin lymphoma (NHL) |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/8791 |
| work_keys_str_mv | AT hastonoridwansyah theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT indrawijaya theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT muhammadhasanbashari theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT achmadhusseinsundawakartamihardja theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT bethysuryawathyhernowo theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT hastonoridwansyah roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT indrawijaya roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT muhammadhasanbashari roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT achmadhusseinsundawakartamihardja roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT bethysuryawathyhernowo roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview |